Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
06. Juni 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights...
Hemispherx Biopharma Board Appoints New President
13. August 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new...
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
26. Mai 2015 12:46 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
11. Mai 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
Hemispherx Biopharma Awarded $770,852 by Federal Judge
15. Januar 2015 08:30 ET
|
AIM ImmunoTech Inc.
WILMINGTON, Del., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that after prevailing in a federal lawsuit brought against the...
Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit
20. Oktober 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that a federal judge in Delaware has dismissed all claims...
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries
10. März 2014 11:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...
Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
10. März 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta...